ITU512 NCT06546670 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 1/2

Clinical phase

Recruiting

Recruitment status

161

Planned enrollment

2028-05-01

Primary-completion proxy

Executive view

NCT06546670 evaluates ITU512 in Anemia, Sickle Cell. The disclosed sponsor is Sponsor not reported, the design is Interventional, and the geographic footprint is United States, Turkey. The first listed primary endpoint is Part 1A, Part 1B, Part 1C: Incidence of AEs and SAEs, assessed over Up to approximately 60 days.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT06546670 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Anemia, Sickle Cell landscape. Drug & Asset MCP drug_fetch was queried for ITU512, while Company & Deal Intelligence MCP organization_fetch was queried for Sponsor not reported.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT06546670	ITU512	Phase 1/2 / Recruiting	Sponsor not reported	United States, Turkey	Part 1A, Part 1B, Part 1C: Incidence of AEs and SAEs Up to approximately 60 days	2028-05-01
PACTR202505486265852	CLY-124	Phase 1 / Recruiting	Cellarity Inc.	Ghana, Kenya		Timing not reported
NCT06930703	Cannabidiol	Phase 1/2 / Recruiting	Icahn School of Medicine at Mount Sinai	United States	Tumor Necrosis Factor-alpha level at 4 weeks	2027-02-01
NCT06924970	Tebapivat	Phase 2 / Terminated	Agios Pharmaceuticals, Inc.	Canada, Netherlands, Belgium, United States, Ireland, United Kingdom, France	Percentage of Participants With Hb Response Baseline, Week 10 through Week 12	2026-05-12
NCT06872333	Fludarabine Phosphate	Phase 2 / Recruiting	University of Minnesota Masonic Cancer Center	United States	Incidence of Graft versus Host Disease (GvHD) 1 year	2030-06-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT06546670 is a Phase 1/2, recruiting study with 161 planned participants. Allocation is Randomized, masking is Double, and the intervention model is Crossover Assignment.

The primary endpoint is “Part 1A, Part 1B, Part 1C: Incidence of AEs and SAEs” over “Up to approximately 60 days.” The retrieved endpoint description is: Number of participants with adverse events (AEs) and serious adverse events (SAEs), including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 161 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

5 recent result records were selected as contextual evidence for Anemia, Sickle Cell. These records do not establish direct evidence for NCT06546670 unless the registration number matches.

A Phase 1/2/3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subject…

Phase 2/3; n=63; Percentage of Participants Who Have Not Experienced Any Severe Vaso-occlusive Crisis (VOC) for at Least 12 Consecutive Months (VF12) After Exa-cel Infusion = 91.3 Percentage of participants (95% Confidence Interval, 79.2 - 97.6) Source: https://clinicaltrials.gov/ct2/show/results/NCT03745287

Evaluation of The Use of Hydroxyurea in Treating Children With Sickle Cell Anemia in Central Africa's Rural Area

Not Applicable; n=69; HbF(12 months) = 3.0 fold Source: https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/42577886/

Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders

Phase 2; n=56; Engraftment = 53 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT01050855

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

ITU512 is indexed as Small molecule drug with target not reported biology and a global stage of Phase 1/2. The asset profile lists Novartis Pharmaceuticals Corp. as an originator or developer.

No exact Company & Deal Intelligence profile was returned for Sponsor not reported. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether ITU512 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT06546670
Protocol source: https://clinicaltrials.gov/study/NCT06546670
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.

ITU512 in Anemia, Sickle Cell is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Part 1A, Part 1B, Part 1C: Incidence of AEs and SAEs and 2028-05-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP